CVD EQUIPMENT CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CVD EQUIPMENT CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $41.13M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $20.96M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $38.97M | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $27.99M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $17.88M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $22.16M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $30.99M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $16.26M | Mar 27, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.79M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $26.88M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $24.11M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $25.81M | Mar 28, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.29M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.05M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $5.07M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $6.63M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.08M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $2.88M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.80M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.18M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $17.60M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $7.10M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.59M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.90M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($4.18M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($224.0K) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.75M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($6.07M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($6.33M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($5.20M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $5.26M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($149.1K) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.91M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($2.42M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($4.88M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($1.82M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($4.66M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($7.82M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.98M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($5.25M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $7.22M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($724.6K) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.79M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.63M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $2.60M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.91M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.79M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $372.6K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $597.5K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $606.6K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $437.2K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $433.8K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.68M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.49M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($206.0K) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $194.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($4.27M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($1.13M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $570.7K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $509.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.38M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $8.85M | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $106.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $418.0K | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $665.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $236.0K | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.58M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.69M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.54M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $889.3K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $112.5K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.51M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $31.69M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $35.03M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $37.91M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $35.52M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $40.94M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $46.72M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $51.84M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $58.98M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $45.60M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.78M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.32M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $8.82M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $8.51M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.34M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $16.81M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $16.77M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $16.12M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $18.32M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $11.29M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.73M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $25.37M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $26.20M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $29.40M | Mar 19, 2025 |
| FY2023 | Dec 31, 2021 | $29.19M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $24.13M | Mar 27, 2023 |
| FY2021 | Dec 31, 2019 | $29.96M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $35.71M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $39.97M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $34.31M | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.04M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($4.46M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($2.56M) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.62M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.84M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($2.90M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.17M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $9.50M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $15.38M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $10.12M | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.73M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $12.60M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $14.03M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $14.37M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $16.65M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $7.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $8.66M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $11.44M | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $14.21M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $21.68M | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $268.0K | Mar 19, 2025 |
| FY2023 | Dec 31, 2023 | $349.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2022 | $426.0K | Mar 27, 2023 |
| FY2022 | Dec 31, 2021 | $1.77M | Mar 27, 2023 |
| FY2020 | Dec 31, 2020 | $13.80M | Mar 31, 2021 |
| FY2019 | Dec 31, 2019 | $12.05M | Mar 30, 2020 |
| FY2018 | Dec 31, 2018 | $12.91M | Apr 1, 2019 |
| FY2017 | Dec 31, 2017 | $13.65M | Apr 2, 2018 |
| FY2016 | Dec 31, 2016 | $3.27M | Mar 30, 2017 |
| FY2016 | Dec 31, 2015 | $3.85M | Mar 30, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.94M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 6.88M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 6.82M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 6.76M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 6.72M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 6.68M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 6.62M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 6.54M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 6.46M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 6.35M | Apr 2, 2018 |